89 - The Impact of Nirsevimab on an RSV Season in All Infants: Data From The HARMONIE Study

Presenting Author(s)

• 

  Saul N. Faust, FRCPCH PhD (he/him/his)

  Professor of Paediatric Immunology and Infectious Diseases
  University of Southampton and University Hospital Southampton NHS Foundation Trust
  Southampton, England, United Kingdom

  Slides

Co-Author(s)

• KC

  Katrina Cathie, MBE, FRCPCH

  University of Southampton
  Southampton, England, United Kingdom
• SD

  SB Drysdale, FRCPCH, PhD

  St George's, University of London
  London, England, United Kingdom
• SR

  S Royal, FRCGP

  University of Nottingham
  Nottingham, England, United Kingdom
• CF

  C Felter, MD

  Sanofi
  Reading, England, United Kingdom
• NV

  NC Vassilouthis, MD

  Sanofi
  Reading, England, United Kingdom
• MB

  Mathieu Bangert, PhD

  Medical
  Sanofi Vaccines, Lyon, France
  Lyon, Rhone-Alpes, France
• KM

  K Mari, PhD

  Sanofi
  Lyon, Rhone-Alpes, France
• RN

  R Nteene, MD

  Sanofi
  Lyon, Rhone-Alpes, France
• MR

  M Roberts, MD

  Sanofi
  Bridgewater, New Jersey, United States
• MK

  M Knuf, MD

  Klinikum Worms
  Worms, Rheinland-Pfalz, Germany
• FF

  F Flamein, MD

  CHU Lille
  Lille, Lorraine, France
• PT

  P Tissieres, MD

  APHP
  Paris, Ile-de-France, France